Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High – Here’s Why

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $10.03 and last traded at $9.79, with a volume of 1176785 shares trading hands. The stock had previously closed at $9.41.

Analyst Ratings Changes

Several equities analysts have issued reports on ZVRA shares. JMP Securities set a $18.00 price objective on Zevra Therapeutics in a research report on Wednesday, March 12th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, May 22nd. Canaccord Genuity Group boosted their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Finally, HC Wainwright assumed coverage on Zevra Therapeutics in a research report on Wednesday. They set a “buy” rating and a $26.00 target price for the company. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Zevra Therapeutics has an average rating of “Buy” and an average target price of $23.14.

Zevra Therapeutics Stock Up 4.0%

The company has a quick ratio of 2.93, a current ratio of 3.02 and a debt-to-equity ratio of 1.46. The firm has a 50 day simple moving average of $8.63 and a 200-day simple moving average of $8.09. The stock has a market cap of $535.04 million, a P/E ratio of -5.15 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15. The firm had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same quarter in the prior year, the company earned ($0.40) earnings per share. On average, equities research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics in the 4th quarter valued at $53,000. GAMMA Investing LLC boosted its holdings in shares of Zevra Therapeutics by 20,564.1% in the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock valued at $60,000 after purchasing an additional 8,020 shares in the last quarter. Strs Ohio acquired a new stake in shares of Zevra Therapeutics in the 1st quarter valued at $125,000. Squarepoint Ops LLC boosted its holdings in shares of Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after purchasing an additional 4,384 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of Zevra Therapeutics in the 4th quarter valued at $145,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.